The Goodes Prize for Excellence in Drug Development honors an innovative researcher who has made a significant and lasting impact in the field.
The Goodes Prize – recognized as the Nobel Prize of Alzheimer’s research – celebrates an exceptional scientist whose groundbreaking work has made a profound and enduring impact on the field of Alzheimer’s research.
At a moment of unprecedented optimism in Alzheimer’s research, it is vital to accelerate progress toward transformative treatments, innovative biomarkers, and strategies that will treat, prevent, and ultimately cure, this disease.
Named in honor of Melvin R. Goodes, a visionary leader in the pharmaceutical industry whose breakthroughs improved millions of lives, the prize recognizes those who embody the same spirit of excellence, ingenuity, and perseverance.
As a global leader in advancing the most promising science, the Alzheimer’s Drug Discovery Foundation is proud to award the Goodes Prize, which includes $150,000 to propel the recipient’s future research and bring us closer to ending Alzheimer’s.
Winners
2015: Frank Longo, MD, PhD
2016: D. Martin Watterson, PhD
2017: Roberta Diaz Brinton, PhD
2018: Michela Gallagher, PhD
2019: Jeffrey Cummings, MD
2020: Jerri M. Rook, PhD
2021: Miia Kivipelto, MD, PhD
2022: Miranda E. Orr, PhD
2023: Rhoda Au, PhD, MBA